Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (8057L)

TIDMHCM

RNS Number : 8057L

Hutchison China Meditech Limited

23 April 2018

Grant of Share Options under Share Option Scheme

London: Monday, April 23, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").

Chi-Med granted 762,690 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

 
 Date of grant             :   April 20, 2018 
 Exercise price of share   :   GBP46.45 per Ordinary Share 
  options granted 
 Number of share options   :   762,690 (each share option 
  granted                       shall entitle the holder 
                                thereof to subscribe for 
                                one Ordinary Share) 
 Closing market price      :   GBP46.45 per Ordinary Share 
  of Ordinary Shares on 
  the date of grant 
 Validity period of the    :   From April 20, 2018 to April 
  share options                 19, 2028 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate Finance 
 & Development                                       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson             [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications                       [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications                      [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                           [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson                  [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                          [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHPGUCUCUPRGPW

(END) Dow Jones Newswires

April 23, 2018 08:10 ET (12:10 GMT)